Company intelligence / Profile preview
Opthea Limited
Melbourne, Victoria, Australiaopthea.com ↗
- Ownership
- Public · OPT
- Development stage
- Phase 3
01
Overview
Opthea Limited is advancing sozinibercept (formerly OPT‑302), a novel biologic targeting VEGF-C and VEGF-D, in two pivotal Phase 3 trials for wet AMD. In Phase 2b studies with ranibizumab, sozinibercept demonstrated superior visual outcomes compared to standard-of-care alone. The ongoing COAST and ShORe Phase 3 trials are fully enrolled with topline results expected in Q2 and mid‑2025 respectively. Sozinibercept could become the first new therapy in two decades to deliver improved vision outcomes for wet AMD patients when used alongside anti–VEGF-A therapies.
- Therapeutic areas
- Ophthalmology
- Modalities
- Biologics (VEGF-C/D ‘trap’ inhibitor)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Opthea Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Opthea Limited.